Core Insights - Barinthus Biotherapeutics plc announced significant data from the Phase 2b HBV003 clinical trial, which will be presented at the AASLD meeting on November 18, 2024 [2][3] - The trial aims to evaluate the immunotherapeutic candidate VTP-300 in combination with low-dose nivolumab for chronic hepatitis B treatment [3][8] Study Details - The HBV003 trial has fully recruited 121 participants, with 69 having HBsAg levels below 200 IU/mL [3] - Eight participants achieved complete HBsAg loss, and two met the criteria for functional cure [3][4] - Two participants who discontinued nucleos(t)ide analogue (NUC) therapy seroconverted to HBsAb positivity [4][5] Treatment Efficacy - The combination of VTP-300 and low-dose nivolumab showed stronger immune responses, with durable HBsAg declines observed across all treatment groups [5][6] - Among 40 participants assessed for NUC discontinuation, 66% (6 out of 9) remained off NUC therapy for over six months, with two achieving functional cure [5][6] Safety Profile - Preliminary safety data indicate that VTP-300 combined with low-dose nivolumab was well tolerated, with no treatment-related serious adverse events reported [5][6] Company Overview - Barinthus Bio is focused on developing immunotherapeutic candidates for chronic infectious diseases and autoimmunity, with VTP-300 being a key component in their pipeline [9]
Barinthus Bio Announces Results From Ongoing Phase 2b Chronic Hepatitis B Trial, Including Achievement of Functional Cure and HBsAb Seroconversion